Indirect treatment comparisons: Choosing the right tool for the job

Abstract

HbA1c and body weight reductions, and that switching from semaglutide 1.0 mg to dulaglutide 4.5 mg may further enhance weight loss. They contrasted their approach to that of Pratley et al., 2 where an indirect treatment comparison using network meta-analysis (NMA) methods was conducted to compare semaglutide 1.0 mg OW with dulaglutide 3.0 or 4.5 mg OW. The conclusion of this analysis was that semaglutide 1.0 mg versus dulaglutide 3.0 or 4.5 mg, respectively, was associated with significantly greater or comparable HbA1c reductions, and that semaglutide 1.0 mg was associated with